An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)

• ClinicalTrials.gov Identifier: NCT00652080
• Recruitment Status: Completed
• First Posted: April 3, 2008
• Results First Posted: February 15, 2019
• Last Update Posted: March 5, 2019
• Sponsor: Berg, LLC
• Information provided by (Responsible Party): Berg, LLC

Study Description

Brief Summary:

The purpose of this study is to determine the safety and tolerability of pharmaceutical compound 31510 in a topical cream when applied to in situ cutaneous squamous cell carcinoma and to obtain preliminary efficacy data for the treatment of in situ cutaneous squamous cell carcinoma by Compound 31510 topical cream.

Condition or disease	Intervention/treatment	Phase
Squamous Cell Carcinoma	Drug: API 31510	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 35 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Study Start Date: June 2008
• Actual Primary Completion Date: January 2010
• Actual Study Completion Date: January 2010

Arms and Interventions

Arm	Intervention/treatment
Experimental: 1; Active Cream 3%; AM & PM	Drug: API 31510; Topical Cream; 3% active; AM & PM application

Outcome Measures

Primary Outcome Measures :

1. Number of Participants With Adverse Events [ Time Frame: 6 weeks ]
   To determine the safety and tolerability of API 31510 cream 3%, topically applied to in situ cutaneous squamous cell carcinomas (SCCIS).

Secondary Outcome Measures :

1. Percentage of Participants With a Complete Response [ Time Frame: 6 weeks ]

   To obtain a preliminary determination of the efficacy of API 31510 cream 3%,topically applied to in situ cutaneous squamous cell carcinomas.

   The subject was considered to have had a complete response only if the histological examination of the target lesion was negative.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Male or female adults > 18 years of age
• Primary, histologically confirmed SCCIS with a minimum area of 0.5 cm2 and with a maximum diameter of 2.0 cm target SCCIS lesion suitable for excision
• Histological diagnosis made no more than 4 weeks prior to the screening visit
• Histological biopsy removed 25% or less of the target lesion
• No other dermatological disease in the SCCIS target site or surrounding area
• Willing to refrain from using non-approved lotions or creams on the target site and surrounding area during the treatment period. Willing to refrain from washing the treated area for at least 8 hours following the application of study medication
• Willing to refrain from exposure to direct sunlight or ultraviolet light and to avoid the use of tanning parlors for the duration of the study
• Laboratory values for the tests listed in the Study Schedule on page 2 within the reference ranges as defined by the central laboratory, or "out of range" test results that are clinically acceptable to the investigator.
• Ability to follow study instructions and likely to complete all study requirements
• Written informed consent obtained, including consent for tissue to be examined and stored by the central dermatopathologist.
• Written consent to allow photographs of the target SCCIS lesion to be used as part of the study data
• For females of childbearing potential, a negative pregnancy test at screening and using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy)

Exclusion Criteria:

• Pregnant or lactating
• Presence of known or suspected systemic cancer
• Histological evidence of nBCC, sBCC, or any other tumor in the biopsy specimen
• Histological evidence of severe squamous metaplasia, infiltrative, desmoplastic or micronodular growth patterns in the biopsy specimen
• History of recurrence of the target SCCIS lesion
• Evidence of dermatological disease or confounding skin condition in the treatment area, e.g., BCC, actinic keratosis, rosacea, psoriasis, atopic dermatitis, eczema, xeroderma pigmentosa
• Concurrent disease or treatment that suppresses the immune system
• Chronic medical condition that in the judgment of the investigator(s) would interfere with the performance of the study or would place the patient at undue risk
• Known sensitivity to any of the ingredients in the study medication
• Use of a tanning parlor or other excessive or prolonged exposure to ultraviolet light or direct sunlight during the course of the study
• Treatment with systemic chemotherapeutic agents within the 6 months prior to the screening visit
• Use of systemic retinoids within the 6 months prior to the screening period
• Treatment with systemic immunomodulators or immunosuppressants within the 6 months prior to the screening period
• Use of topical immunomodulators within 2 cm of the target SCCIS lesion within the 4 weeks prior to the screening period
• Treatment with the following topical agents within the 4 weeks prior to the screening visit; levulinic acid, 5-fluorouracil, corticosteroids, retinoids, diclofenac, hyaluronic acid, imiquimod
• Undergone a facial resurfacing procedure, i.e., chemical peel, laser resurfacing, dermabrasion, within the 6 months prior to the screening visit, if the target SCCIS lesion is on the face
• Treatment with liquid nitrogen, surgical excision or curettage within 2cm of the target SCCIS lesion during the 4 weeks prior to the screening visit
• Elective surgery within 4 weeks prior to the screening visit, during the study, or 4 weeks after the treatment period
• Evidence of current chronic alcohol or drug abuse
• Current enrollment in an investigational drug or device or participation in such a study within 4 weeks of the screening visit
• In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions of the protocol and complete the study

Contacts and Locations

Locations

United States, Arkansas

Burke Pharmaceuticals

Hot Springs, Arkansas, United States, 71913

United States, California

Skin Surgery Medical Group, Inc.

San Diego, California, United States, 92117

United States, Illinois

Glazer Dermatology

Buffalo Grove, Illinois, United States, 60089

United States, New York

Long Island Skin Cancer and Dermatalogic Surgery, PC

Smithtown, New York, United States, 11787

United States, Virginia

Education and Research Foundation

Lynchburg, Virginia, United States, 24501

Sponsors and Collaborators

Berg, LLC

More Information

• Responsible Party: Berg, LLC
• ClinicalTrials.gov Identifier: NCT00652080
• Other Study ID Numbers: CTL0408
• First Posted: April 3, 2008
• Results First Posted: February 15, 2019
• Last Update Posted: March 5, 2019
• Last Verified: February 2019

Additional relevant MeSH terms:

Carcinoma; Carcinoma, Squamous Cell; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Squamous Cell